BASF may revisit Evonik bid: Evonik stock sits 2.56 percent below 52-week high

Published on 10/16/2026 at 09:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evonik stock costs EUR 21.28 on October 16, 2026, 0.19 percent below the Xetra close. Parmantier set EUR 20.50 on October 6, 2026.

Takeover talk and valuation

Reuters reported on October 9, 2026, that BASF could submit another offer after a EUR 22.15 bid was rejected.
Parmantier & Cie. set a Hold rating and EUR 20.50 target on October 6, 2026.
Evonik stock trades at EUR 21.28 at 9:20 a.m. CEST at Lang & Schwarz on October 16, 2026, minus 0.19 percent below the Xetra close of October 15, 2026.

Draufsicht auf Aktienzertifikat, ISIN-Karte DE000EVNK013 und Spezialchemie-Laborutensilien auf Marmor — Evonik Industries DE000EVNK013 als Flatlay mit Aktienzertifikat, ISIN-Karte und Chemielabor-Utensilien auf Marmor, Illustration mit AI erstellt.

Evonik (ISIN DE000EVNK013) was trading at EUR 21.28 at Lang & Schwarz on October 16, 2026, 0.19 percent below the Xetra close of October 15, 2026. The latest catalyst is takeover speculation after BASF considered another offer for the specialty chemicals group.

BASF bid keeps valuation in play

Yahoo Finance reported on October 9, 2026, that BASF could submit another bid after Evonik rejected an earlier proposal of EUR 22.15 per share in September. The earlier offer was valued at EUR 10.3 billion, while the latest market price remains below the EUR 21.84 52-week high.

Three dates changed the setup

On September 25, 2026, EQS News documented Evonik's receipt of a non-binding BASF approach. On October 6, 2026, the same source published Parmantier & Cie.'s EUR 20.50 target. On October 9, 2026, Yahoo Finance carried the report about a possible renewed BASF offer at EUR 22.15 per share.

What does the target imply?

EQS News said Parmantier & Cie. rated Evonik Hold with a six-month target of EUR 20.50 on October 6, 2026. That target is EUR 0.78 below the Lang & Schwarz price, putting the research view below the current quotation rather than alongside the higher takeover scenario.

Reporting dates set the next test

Evonik is scheduled to publish its third-quarter 2026 report on November 3, 2026, according to the company's investor-relations page. The same calendar lists fourth-quarter 2026 reporting for March 4, 2027, giving investors a defined timetable for testing the takeover narrative against operating performance.

Stock stays below yearly high

The 52-week range is EUR 12.49 to EUR 21.84, and market capitalization is EUR 9.9 billion as of October 16, 2026. For investors, the next valuation signal comes from the balance between a potential BASF premium and the company's upcoming earnings report.

Evonik stock was trading at EUR 21.28 at Lang & Schwarz on October 16, 2026 at 9:20 a.m. CEST, minus 0.19 percent versus the Xetra close of October 15, 2026 (EUR 21.32). The further course of trading is shown by the continuously updated real-time quote of Evonik stock.